Ulnar Wrist Pain Treatment With Dextrose Prolotherapy

May 2, 2021 updated by: Ezequiel Mailand and Miguel Slullitel, Universidad Abierta Interamericana

Dextrose Prolotherapy in Chronic Ulnar Wrist Pain Resistant to Usual Care: Comparison to a Naive-to-treatment Cohort Who Receive Usual Care

Participants who have failed therapy for chronic wrist pain on the little finger side of the wrist will recieve dextrose prolotherapy. Their results will be compared to a cohort of consecutive participants who have not failed therapy, and receive 4 weeks of usual care.

Study Overview

Status

Recruiting

Conditions

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Santa Fe
      • Rosario, Santa Fe, Argentina, 2000
        • Recruiting
        • Scanner Centro de Diagnostico
        • Contact:
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

17 years to 66 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria

  • Pain on the ulnar side of the wrist.
  • PRWE greater than 40

Exclusion criteria

  • Radioulnar instability more than moderate as determined by a positive ulna fovea sign or ulna grinding test
  • Surgery in the wrist area
  • Infection in the wrist area
  • Other wrist pathology on examination
  • Other pain area that is constant, interferes with sleep, or is as bad, or worse, than shoulder pain.
  • Diabetes or other peripheral neuropathy
  • Radiculopathy
  • Unstable psychiatric function.
  • Current opioid use.
  • Vulnerable patients
  • Pregnancy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Usual Care
Therapeutic ultrasound, myofascial release of extensor and flexor muscles of forearm and stabilization exercises for the wrist.
Experimental: Dextrose
Injection of 1 ml of 12.5% dextrose in 1% lidocaine at 0, 3 and 6 weeks in 5 locations: Origin of ulnar collateral ligament, insertion of ulnar collateral ligament on the triquetrum, insertion of the extensor carpi ulnaris on the base of the 5th metacarpal, triquetral hamate ligament and ulnotriquetral joint space.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from Baseline PRWE (Patient Rated Wrist Evaluation) at 9 weeks
Time Frame: 9 weeks
The PRWE is a 15-item questionnaire designed to measure wrist pain and disability in activities of daily living.
9 weeks
Change from baseline PRWE between 0 weeks and 1 year
Time Frame: 1 year
1 year
Percentage of participants exceeding a PRWE change of plus 14 between baseline and 9 weeks
Time Frame: 9 weeks
9 weeks
Percentage of participants exceeding a PRWE change of plus 14 between baseline and 1 year
Time Frame: 1 year
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Satisfaction score at 9 weeks
Time Frame: 9 weeks
On a scale from 1-5 please rate satisfaction with your results. 1 means 'no satisfaction' and 5 means 'complete satisfaction'.
9 weeks
Satisfaction score at 1 year
Time Frame: 1 year
On a scale from 1-5 please rate satisfaction with your results. 1 means 'no satisfaction' and 5 means 'complete satisfaction'
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Miguel Slullitel, M.D., Universidad Abierta Interamericana

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2018

Primary Completion (Anticipated)

January 1, 2022

Study Completion (Anticipated)

January 1, 2023

Study Registration Dates

First Submitted

January 3, 2018

First Submitted That Met QC Criteria

January 19, 2018

First Posted (Actual)

January 26, 2018

Study Record Updates

Last Update Posted (Actual)

May 4, 2021

Last Update Submitted That Met QC Criteria

May 2, 2021

Last Verified

May 1, 2021

More Information

Terms related to this study

Other Study ID Numbers

  • UniversidadAI

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

IPD Plan Description

Anticipate sharing data by request

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Ulnar Wrist Pain

Clinical Trials on Usual Care

Subscribe